EVENITY 105 mg SmPC: Uses, Dosing, Safety
Quick summary EVENITY 105 mg is a pre-filled pen containing romosozumab, used for severe osteoporosis in postmenopausal women at high risk of fracture. It is given as two subcutaneous injections once monthly, usually for...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
EVENITY 105 mg is a pre-filled pen containing romosozumab, used for severe osteoporosis in postmenopausal women at high risk of fracture. It is given as two subcutaneous injections once monthly, usually for 12 months, with calcium and vitamin D support as advised in the official product information.
Medical disclaimer
This article is a general summary of the SmPC-style content and is not a substitute for the official leaflet, prescribing information, or advice from a qualified healthcare professional. Always confirm the latest instructions, warnings, and suitability for the individual patient with the official product information.
What is EVENITY 105 mg solution for injection in a pre-filled pen?
EVENITY contains romosozumab, a monoclonal antibody used in the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
The product is supplied as a 105 mg solution for injection in a pre-filled pen. According to the source content, it is given as two subcutaneous injections once a month.
As with other osteoporosis treatments, the official product information should be checked for the full indication, administration instructions, and patient selection criteria.
How is EVENITY administered?
EVENITY is administered by subcutaneous injection. The source content states that treatment is given as two 105 mg injections once monthly.
- Injection sites mentioned in the source content include the abdomen, thigh, or upper arm.
- Sites should be rotated to help reduce local irritation.
- The pen should be allowed to reach room temperature before use, according to the source content.
Administration may be carried out by a healthcare professional, and the source content also notes that self-administration may be possible where appropriate training has been provided.
What does the source content say about treatment duration?
The source content describes a 12-month treatment period. It also states that patients should maintain adequate calcium and vitamin D intake during treatment.
After the 12-month course, the source content notes that transition to an antiresorptive therapy is recommended to help maintain benefit. Any treatment sequence should be confirmed against the official prescribing information and the patient’s clinical plan.
What clinical evidence is mentioned?
The original content refers to clinical studies showing that romosozumab reduced fracture risk in postmenopausal women with osteoporosis.
It mentions one pivotal study with 7,180 participants and another trial with 4,093 women, including comparison with alendronate and follow-on denosumab therapy.
These details support the article’s summary of the product, but the full study design, endpoints, and results should be reviewed in the official SmPC and related clinical documentation.
What are the contraindications and key precautions?
The source content states that EVENITY should not be used in patients with:
- Hypersensitivity to any component
- Hypocalcaemia
- A prior history of myocardial infarction or stroke
It also highlights the need for caution and monitoring in patients with renal impairment, especially severe renal issues, because calcium levels may need attention.
Before treatment is considered, the source content says that a thorough medical history should be reviewed to help assess cardiovascular risk.
What side effects are mentioned?
The source content lists the following potential adverse effects:
- Injection site reactions
- Headache
- Musculoskeletal pain
It also notes that cardiovascular events are a concern and that patients with a history of heart disease should be monitored closely.
Any new, persistent, or worrying symptoms should be discussed with a healthcare professional promptly.
How does EVENITY compare with other osteoporosis treatments?
The original content says EVENITY showed superior effectiveness to alendronate in reducing new spinal fractures in the first year of treatment.
It also describes romosozumab as having a distinctive mechanism, with effects on both bone resorption and bone formation. This dual action is presented in the source content as a key difference from traditional osteoporosis therapies.
Choice of treatment depends on the patient’s fracture risk, medical history, and the full prescribing information.
Key product points at a glance
| Topic | Summary from the source content |
|---|---|
| Active ingredient | Romosozumab |
| Presentation | 105 mg solution for injection in a pre-filled pen |
| Route | Subcutaneous injection |
| Frequency | Once monthly |
| Duration mentioned | 12 months |
| Key precautions | Hypocalcaemia, hypersensitivity, and prior MI or stroke are highlighted in the source content |
Frequently asked questions
▸ Where is the best place to inject EVENITY?
The source content lists the abdomen, thigh, or upper arm as injection sites. Sites should be rotated, and areas with bruising, scarring, or skin problems should be avoided.
▸ What is the active ingredient in EVENITY?
The active ingredient is romosozumab.
▸ What are the main precautions mentioned in the source content?
The source content highlights hypersensitivity, hypocalcaemia, and a history of myocardial infarction or stroke. It also notes the need for caution in renal impairment.
▸ What side effects are mentioned?
Injection site reactions, headache, and musculoskeletal pain are listed in the source content. Cardiovascular events are also noted as an important safety concern.
▸ How long is treatment described as lasting?
The source content describes a 12-month treatment period, followed by transition to an antiresorptive therapy.
▸ What should be checked before use?
Readers should verify the official SmPC or leaflet for the latest dosing instructions, warnings, and suitability for the individual patient.
Safety reminder: This summary is for general information only. Do not use it to self-diagnose or to make treatment decisions. Always check the official product information and speak with a qualified healthcare professional about any medicine-related questions.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.